Investment Thesis
Marker Therapeutics faces severe fundamental deterioration with revenue collapsing 46.2% YoY to only $751.7K, operating losses of $4.1M, and persistent negative returns on equity and assets. While a strong cash position ($14.9M) and zero debt provide near-term runway of ~10 years at current burn rates, the absence of visible growth catalysts, declining revenue, and unsustainable operating losses indicate a failed or severely distressed business model requiring restructuring.
Strengths
- Exceptional cash reserves of $14.9M relative to total liabilities of $3.6M providing substantial operational runway
- Zero long-term debt and excellent liquidity ratios (4.79x current ratio) minimizing financial distress risk in near term
- Improving EPS trajectory year-over-year (+33.6%) despite ongoing losses suggesting cost control efforts
Risks
- Severe revenue contraction of 46.2% YoY with minimal revenue base of $751.7K indicating failed product commercialization or market rejection
- Operating losses of $4.1M on near-zero revenue demonstrate fundamentally non-viable business economics with -541.8% operating margin
- Negative ROE (-23.0%) and ROA (-18.2%) indicate systematic shareholder value destruction with no path to profitability evident
- Continuous operating cash burn of $1.4M annually suggests unsustainable cash consumption despite minimal operational activity
- Absence of disclosed clinical pipeline progress, product approvals, or strategic partnerships indicating stalled development
Key Metrics to Watch
- Revenue trend stabilization - critical to identify whether decline continues or reverses with new product launches
- Operating cash flow dynamics - monthly burn rate and cash runway exhaustion timeline
- Pipeline advancement disclosures - FDA approvals, clinical trial progress, or licensing deals indicating future revenue potential
Financial Metrics
Revenue
751.7K
Net Income
-3.2M
EPS (Diluted)
$-0.16
Free Cash Flow
-1.5M
Total Assets
17.4M
Cash
14.9M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-541.8%
Net Margin
-423.0%
ROE
-23.0%
ROA
-18.2%
FCF Margin
-200.1%
Balance Sheet & Liquidity
Current Ratio
4.79x
Quick Ratio
4.79x
Debt/Equity
0.00x
Debt/Assets
20.9%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-23T08:48:54.993391 |
Data as of: 2026-03-31 |
Powered by Claude AI